原发性二尖瓣反流行外科二尖瓣修复术的风险
基于美国胸外科医师学会成人心脏外科数据库2014年7月至2020年6月连续53,462例意向治疗的原发性二尖瓣反流行二尖瓣修复术患者,建立病因及术式特异性风险模型。30天手术死亡率1.16%,死亡和/或主要并发症率8.88%,转为置换率6.36%;转为置换者死亡率3.18%高于修复者1.02%,项目手术量越大所有事件率越低。
要点
- 原发性二尖瓣反流行二尖瓣修复术的30天死亡率为1.16%,绝大多数患者风险低于1%。
- 转为置换患者死亡率3.18%,高于修复患者的1.02%。
- 项目手术量越大,所有事件发生率越低。
核心结论
- 该病因及术式特异性风险模型表明,当代原发性二尖瓣反流行二尖瓣修复术的死亡风险在绝大多数患者中低于1%。
研究设计与样本
- 利用美国胸外科医师学会成人心脏外科数据库,纳入2014年7月至2020年6月连续53,462例意向治疗的原发性二尖瓣反流行二尖瓣修复术患者,建立30天手术死亡率、死亡和/或主要并发症及转为置换的风险模型。
主要发现
- 死亡率为1.16%(n=619),死亡加主要并发症率为8.88%(n=4746),转为置换率为6.36%(n=3399)。
- 转为置换患者死亡率3.18%,高于修复患者的1.02%。
- 所有事件率随项目手术量增加而降低。
- 死亡率风险模型区分度优良(AUC:0.807),校准良好,平均死亡风险1.16%,中位数0.55%(四分位距:0.30%-1.17%),第90和第95百分位数分别为2.48%和3.99%。
- 年龄<65岁患者死亡风险<0.5%,各年龄组总人群中97%风险<3%;75岁及以上患者中仅四分之一估计死亡风险>3%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Risk estimation for surgical intervention is an essential component of heart team shared decision-making. However, current mitral valve (MV) surgery risk models used in practice lack etiologic or procedural specificity. The purpose of this study was to establish a comprehensive method for assessment of operative risk of MV repair of primary mitral regurgitation (MR). METHODS: A novel etiology and procedure-specific algorithm identified 53,462 consecutive (July 2014 to June 2020) intention-to-treat MV repair patients with primary MR from The Society of Thoracic Surgeons Adult Cardiac Surgery Database. Risk models were fit for 30-day operative mortality, mortality and/or major morbidity, and conversion-to-replacement (CONV). As-treated mortality and morbidity models were derived separately. RESULTS: Event rates for mortality (n = 619; 1.16%), mortality plus morbidity (n = 4746; 8.88%), and CONV (n = 3399; 6.36%) were low. Mortality was higher in CONV patients vs repair (3.18% vs 1.02%). All event rates were lower with increasing program volumes. The mortality risk model had excellent discrimination (AUC: 0.807) and calibration and confirmed very low mortality risk for isolated MV repair for primary MR, with mean mortality risk of 1.16% and median of 0.55% (interquartile range: 0.30%-1.17%) with 90th and 95th percentiles 2.48% and 3.99%, respectively. The mortality risk was <0.5% in patients <65 years of age, with 97% of the total population across age groups having a risk of <3%. Only 1 in 4 patients age 75 or older had >3% estimated risk of mortality. CONCLUSIONS: This etiologic and procedure-specific risk model establishes that the contemporary mortality risk of MV repair for primary MR is <1% for the vast majority of patients.
引用
- Badhwar V, Chikwe J, Gillinov AM, et al. Risk of Surgical Mitral Valve Repair for Primary Mitral Regurgitation. Ann Thorac Surg. 2023. PMID: 36669963. doi:10.1016/j.athoracsur.2022.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。